1 edition of Clinical effectiveness and cost-effectiveness of pioglitazone for type 2 diabetes mellitus found in the catalog.
Clinical effectiveness and cost-effectiveness of pioglitazone for type 2 diabetes mellitus
Includes bibliographical references.
|Statement||J. Chilcott ... [et al.].|
|Series||Health technology assessment -- v.5, no.19|
|Contributions||Chilcott, J., National Co-ordinating Centre for HTA (Great Britain)|
|The Physical Object|
|Pagination||iv, 71p. :|
|Number of Pages||71|
The linking of a metabolic model and a long-term economic model of health care for Type 2 diabetes mellitus (the Diabetes Decision Analysis of Cost Type 2, DiDACT) allowed the authors to account for the long-term natural history, including long-term complications as well as associated costs, resource use and health outcomes. ACTOS (pioglitazone hydrochloride) is an oral antidiabetic agent that acts primarily by decreasing insulin resistance. ACTOS is used in the management of type 2 diabetes mellitus (also known as non-insulin-dependent diabetes mellitus (NIDDM) or adult-onset diabetes). Pharmacological studies indicate that ACTOS improves sensitivity to insulin.
apy in patients with type 2 diabetes mellitus (T2 DM) in China. Methods: Literature sc reening, meta-analy sis and indirect compa rison were used to compare efficacy and safety between dapaglifl. Cost-effectiveness of Rosiglitazone Combination Therapy for the Treatment of Type 2 Diabetes Mellitus in the UK Article Literature Review in PharmacoEconomics 24 Suppl 1(Suppl 1)
Cost-effectiveness of adding dapagliflozin to insulin for the treatment of type 2 diabetes mellitus in the Netherlands. Clinical Drug Investigation. 34 (2), –46 (). CASAuthor: Rana Moustafa Al AdAwi, Zainab Jassim, Dina Elgaily, Hani Abdelaziz, Bhagya Sree, Mohamed Izham Moha. Pioglitazone was generally well tolerated in patients with type 2 diabetes in clinical trials of up to years’ duration when used as monotherapy and in combination with other drugs including metformin, a sulfonylurea, repaglinide or : John Waugh.
General requirements and performance standards for shipborne radiocommunications and navigational equipment
Modeling of the liquid-phase thermal cracking kinetics of Athabasca bitumen and its major chemical fractions.
Handbook of accounting practice
Investment information sources
Charlie is my darling
Fertilizer placement for potatoes
The best of the Gallup management journal, 2001-2007
Notes and illustrations of the parables of the New-Testament, arranged according to the time in which they were spoken.
Native American folklore, 1879-1979
Protecting our food
The shepherd Psalm
Analysis of ground-liner interaction for tunnels
Cases in collective bargaining and industrial relations
Supercomputing research advances
Clinical effectiveness. The clinical evidence available showed that glitazones reduce glycosylatedhaemoglobin by approximately 1%, and are more effective at higher doses than at lowerdoses.
Glitazone treatment is associated with weight gain. No published data wereavailable on the long-term effects of glitazone by: The clinical effectiveness and cost-effectiveness of pioglitazone for type 2 diabetes mellitus: a rapid and systematic review.
Chilcott J(1), Wight J, Lloyd Jones M, Tappenden P. Author information: (1)University of Sheffield School of Health and Related Research, by: Clinical effectiveness and cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: a systematic review and economic evaluation.
C Czoski-Murray, E Warren, J Chilcott, C Beverley, MA Psyllaki, and J Cowan. Author InformationCited by: Clinical effectiveness In both monotherapy and combination therapy, pioglitazone appeared to be effective in reducing blood glucose in patients with poorly controlled type 2 diabetes.
Background: The aim of this study was to project health-economic outcomes relevant to the German setting for the addition of pioglitazone to existing treatment regimens in patients with type 2 diabetes, evidence of macrovascular disease and at high risk of cardiovascular events.
Methods: Event rates corresponding to macrovascular outcomes from the Prospective Pioglitazone Clinical Trial in Cited by: Pioglitazone for type 2 diabetes mellitus Diseases of the heart and blood vessels account for approximately 70% of all mortality in people with diabetes.
Compared to their non-diabetic counterparts the relative risk of mortality caused by disorders of the heart and blood vessels is two to three for men and three to four for women with diabetes.
The perspective of the analysis is on direct medical costs with a specific focus on the UK NHS. costs. Clinical benefits are discounted at %, and costs are discounted at 6%. Cohort information. One of the key distinctions between the models is the focus on either type 1 or type 2 diabetes.
Type 2 diabetes mellitus (T2DM) is a serious, chronic, and progressive disease that is rapidly increasing in prevalence. The disease now affects >10% of adults in some developed countries, increasing most in Asia. People with T2DM are two to four times more likely to develop a serious cardiovascular (CV) outcome compared with those without by: The PROspective pioglitAzone Clinical Trial In macroVascular Events (PROactive) study was the first randomized, double-blind outcome study in patients with type 2 diabetes managed with diet and/or oral blood glucose-lowering drugs and/or insulin who had a history of macrovascular disease, assessing the effect of pioglitazone on the secondary Cited by: 8.
Lifestyle Modification. In the past decade, several randomized, controlled clinical trials have examined the role of diet and exercise in the prevention of type 2 diabetes. 4 One of the earliest studies was conducted in a Chinese community among men and women with impaired glucose tolerance who were randomized to a program of diet, exercise, or both.
5 Dietary intervention focused Cited by: For cost-effectiveness analysis-required disease progression simulation, United Kingdom Prospective Diabetes Study Outcomes model and Slovenian type 2 diabetes patient cohort were used.
The intervention duration was set to 1, 2, 5, and 10 by: 1. Reviews and ratings for pioglitazone when used in the treatment of diabetes, type 2. 41 reviews submitted/10(3). The clinical effectiveness and cost-effectiveness of pioglitazone in type 2 diabetes mellitus: a rapid and systematic review Chilcott, J., Wight, J., Lloyd Jones, M.
et al. (1 more author) () The clinical effectiveness and cost-effectiveness of pioglitazone in type 2 diabetes mellitus: a rapid and systematic by: To evaluate the cost-effectiveness of pioglitazone versus placebo, given in addition to existing treatment regimens, in patients with type 2 diabetes and evidence of macrovascular disease in.
Chilcott J, Wight J, Lloyd Jones M, Tappenden P. The clinical effectiveness and cost-effectiveness of pioglitazone for type 2 diabetes mellitus: a rapid and systematic review.
Health Technology Assessment ; 5(19): Palmer AJ, Roze S, Valentine WJ, et al. The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making.
Curr Med Res Opin ;S5-S UKPDS Group. UK prospective diabetes study Objective: The long-term cost-effectiveness of using pioglitazone plus metformin (Actoplusmet) compared with rosiglitazone plus metformin (Avandamet) in treating type 2 diabetes (T2DM) was assessed from a US third-party payer perspective.
Research design and methods: Clinical efficacy (change in HbA 1c and lipids) and baseline cohort parameters were extracted from a 12 Cited by: 6. Final Appraisal Determination Clinical effectiveness and cost effectiveness of glitazones for the treatment of type 2 diabetes 1 Guidance For people with type 2 diabetes, the use of a glitazone as second-line therapy added to either metformin or a sulphonylurea - as an alternative to treatment.
Evidence for the Prevention of Type 2 Diabetes Mellitus strong clinical significance in decreasing the incidence of T2DM by % compared with % in the placebo group. 16 Pioglitazone also showed strong clinical significance, Cost-Effectiveness of Diabetes by: 1.
have analyzed the cost-effectiveness of thiazolidinediones for diabetes prevention. The Cost-effectiveness of Diabetes Treatment The cost-effectiveness of diabetes prevention can be compared with that of diabetes treatment, specifically intensive glycemic management, blood pressure management and lipid management (Table 2) (27–33).File Size: 74KB.
Given the results of these trials, we assessed the cost effectiveness of the use of pioglitazone as a first-line therapy in Canada. Methods: A Markov model was used to determine the health outcomes and economic impact for patients with type 2 diabetes, from the perspective of a provincial ministry of by: The prospective cost effectiveness study was conducted for 6 months period in patients who were diagnosed with type-2 diabetes mellitus and were receiving treatment specifically with oral.Title:Real-World Clinical Effectiveness and Tolerability of Hydroxychloroquine Mg in Uncontrolled Type 2 Diabetes Subjects who are not Willing to Initiate Insulin Therapy (HYQ-Real-World Study) VOLUME: 15 ISSUE: 6 Author(s):Amit Gupta* Affiliation:G.D.
Diabetes Institute, Kolkata, West Bengal Keywords:Hydroxychloroquine, insulin therapy, type 2 diabetes, HbA1c, clinical effectiveness, HYQ Author: Amit Gupta.